Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
N-ARYLOXYPROPANOLYL-N’-PHENETHYL-UREA
Document Type and Number:
WIPO Patent Application WO/2005/063699
Kind Code:
A1
Abstract:
The present invention provides N-aryloxypropanolyl-N’-phenethyl-urea derivatives of formula (3), method for their preparation and use thereof as potent appetite suppressants for treatment of obesity. Formula (3): wherein R is selected from the group consisting of H, 2, 3, or 4-trifluoromethyl, 2, 3, or 4-chloro, 2, 3, or 4-bromo, 4-acetyl, 4-propionyl, 4-acetamido, 2, 3 or 4 methoxy, 4 nitrile, 2, 3 or 4-methyl, and 4 formyl and X is S or O.

Inventors:
BHANDARI KALPANA
SRIVASTAVA SHIPRA
NATH CHANDESHWAR
Application Number:
PCT/IN2003/000470
Publication Date:
July 14, 2005
Filing Date:
December 31, 2003
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
COUNCIL SCIENT IND RES (IN)
International Classes:
C07C275/24; C07C335/12; (IPC1-7): C07C275/24
Domestic Patent References:
WO2000035875A12000-06-22
Foreign References:
EP0798291A11997-10-01
EP0738711A11996-10-23
EP0955293A11999-11-10
Attorney, Agent or Firm:
Subramaniam, Hariharan (Nataraj & Associates E-55, Greater Kailash-II New Delhi 8, IN)
Download PDF:
Claims:
We claim :
1. NaryloxypropanolylN'phenethyl urea of general formula 3 wherein R is selected from the group consisting of H, 2,3 or 4trifluoromethyl, 2,3, or 4chloro, 2,3, or 4bromo, 4 acetyl, 4propionyl, 4acetamido, 2,3 or 4 methoxy, 4 nitrile, 2,3 or 4methyl and 4 formyl and X is S or O.
2. Formula 3.
3. A compound of formula 3 a claimed in claim 1 selected from the group consisting of. 3a. N [2hydroxy3 (4trifluoromethylphenoxy) propyl] N'2phenethylurea. 3b. N [2hydroxy3phenoxypropyl]N'2phenethylurea 3c. N [2hydroxy3 (3trifluoromethylphenoxy) propyl] N'2phenethylurea. 3d. N [3 (4chlorophenoxy)2hydroxypropyl]N'2phenethylurea. 3e. N [3 (4bromophenoxy)2hydroxypropyl]N'2phenethylurea. 3f. N [3 (4acetylphenoxy)2hydroxypropyl]N'2phenethylurea. 3g. N [2hydroxy3 (4propionylphenoxy) propyl] N'2phenethylurea. 3h. N [3 (4acetamidophenoxy)2hydroxypropyl]N'2phenethylurea. 3i. N [2hydroxy3 (2methoxyphenoxy) propyl] N'2phenethylurea. 3j. N [2hydroxy3 (4methoxyphenoxy) propyl] N'2phenethylurea. 3k. N [3 (4cyanophenoxy)2hydroxypropyl]N'2phenethylurea.
4. 31 N [2hydroxy3 (2methylphenoxy) propyl] N'2phenethylurea. 3m. N [2hydroxy3 (3methoxyphenoxy) propyl] N'2phenethylurea. 3n. N [2hydroxy3 (4trifluoromethylphenoxy) propyl] N'2phenethylthiourea 3o. N [2hydroxy3 (4propionylphenoxy) propyl] N'2phenethylthiourea.
5. 3p. N [2hydroxy3 (4methoxyphenoxy) propyl] N'2phenethylthiourea.
6. A process for the preparation of NaryloxypropanolylN'phenethyl urea derivatives of the formula 3 Formula 3 wherein X is S or O and R is selected from the group consisting of H, 2,3 or 4 trifluoromethyl, 2,3, or 4chloro, 2,3, or 4bromo, 4acetyl, 4propionyl, 4acetamido, 2,3 or 4 methoxy, 4 nitrile, 2,3 or 4methyl and 4formyl, the process comprising reacting a substituted phenolic compound with epichlorohydrin in the presence of alkali carbonate to obtain the corresponding phenoxy epoxy propane which is then reacted with ammonium hydroxide to obtain aminoalcohol of formula 1 OH O NH2 Y D.
7. Formula 1 wherein R is as given above, which is then reacted with a cyanate compound of formula 2 wherein X is oxygen or sulphur N Formuala 2 to obtain the compound of formula 3 4 : A process as claimed in claim 3 wherein the alkali carbonate is selected from K2CO3 and Na2C03.
8. A process as claimed in claim 3 wherein the reaction between compound of formula 1 and compound of formula 2 is carried out in an aprotic solvent selected from the group consisting of CH3CN, CHC13, CH2C12. THF and 1, 2Dichloroethane.
9. A process as claimed in claim 3 wherein the reaction between compound of formula 1 and compound of formula 2 is carried out at a temperature in the range of 1550°C for a period ranging between 518 hrs.
10. A process as claimed in claim 3 wherein the reaction between compound of formula 1 and compound of formula 2 is carried out in equimolar proportions of compound land compound 2.
11. A pharmaceutical composition comprising compound of formula. 3 with one or more conventional additives.
12. A method for the treatment of obesity comprising administering to a subject suffering from obesity, a pharmaceutically effective amount of compound of formula 3.
13. A method as claimed in claim 9 wherein the compound of formula 3 is administered in the form of a pharmaceutical composition of compound of formula 3 with pharmaceutically acceptable additives.
14. Use of compound of formula 3 alone or with one or more pharmaceutically acceptable excipients for the treatment of obesity.
15. Use as claimed in claim 11 wherein N [2hydroxy3 [4trifluoromethylphenoxy] propyl] N'2phenethylurea (3a) shows same activity as Sibutramine.
16. Use as claimed in claim 11 wherein (N [2hydroxy3 (4 trifluoromethylphenoxy) propyl] N'2phenethylurea, showed a decrease of 41.42% in food intake as compared to food intake in the control group.
17. Use as claimed in claim 11 wherein (N [2hydroxy3 (4 methoxyphenoxy) propyl] N'2 phenethylurea (compound 3j), showed decrease of 31.82% in food intake as compared to food intake in the control group.
18. Use as claimed in claim 11 wherein (N [2hydroxy3 (4 trifluoromethylphenoxy) propyl] N'2phenethylthiourea (compound 3n), showed decrease of 28.4% in food intake as compared to food intake in the control group.
Description:
N-ARYLOXYPROPANOLYL-N'-PHENETHYL-UREA Field of the invention The presently invention relates to novel n-aryloxypropanolyl-N'-phenethyl-urea. The present invention particularly relates to the synthesis of novel N-aryloxypropanolyl-N'- phenethyl-urea derivatives of formula 3 and their use as potent appetite suppressants for treatment of obesity Formula 3 wherein R is selected from the group consisting of H, 2,3 or 4-trifluoromethyl, 2,3, or 4- chloro, 2,3, or 4-bromo, 4-acetyl, 4-propionyl, 4-acetamido, 2,3 or 4 methoxy, 4 nitrile, 2,3 or 4-methyl, and 4 formyl and X is S or O.

Background of invention Obesity is now a common disorder in the industrialized as well as in the developing countries. It is estimated that somewhere between 34 and 61 million people in the USA are obese and in much of the developing countries the incidence is increasing by about 1% per year. It is responsible for various adverse effects on health being associated with an increase in morbidity and mortality from diabetes, hypertension, cardiovascular diseases and certain forms of cancer.

There are only two drugs currently available for the long term treatment of obesity in United States. One of these, sibutramine (Ryan, D. H., Kaiser, P. , Bray, G. A.

Obes. Res. 1995,3 : 553S-9S ; Jones, S. P. , Smith, I. G. , Kelly, F. , Gray, J. A. Int J Obes RelatMetab Disord 1995,19 : 41), the only F D A approved drug, suppresses appetite by altering norepinephrine and 5HT metabolism in the brain. The other drug, orlistat (Int J Obes Relat Metab disord 1997,21 : S12-S23), reduces fat absorption by inhibiting gastric, pancreatic and other gastrointestinal lipases. The results of long-term clinical trials, extensive information of clinical effectiveness and side effects, however indicate that both of these drugs are of limited efficacy (Hill, J. O., Haupman, J. , Anderson, J. W. Am J Clin Nutr 1999,69 : 1108-16; <BR> <BR> <BR> <BR> Sjostrom, L. , Rissanen, A., Anderson, T. Lancet 1998, 352: 167-172; Davidson, M. H., Hauptman, J. , DiGirolamo, M. etal, J Am Med Assoc 1999, 281 : 235-42; Hollander, P. A., Elbein, S. C., Hirsch, I. B. etalDiabetes Care 1998,21 : 1288-94; Kaiser, P. E. & Hinson, J. L.

J Clin. Pharmacol 1994,34, 1019; Bray, G. A. Obes Res 7,1999, 189-198 ; Fanghanel, G.,

Cortinas, L., Sanchez-Reyes, L. , Berber, A., Int. J. Obes. 2000,24 (2), 144-150; Cuellar, Guillermina, Elisa Martinez ; Ruiz, Alberto Martinez; Monsalve, Maria Cristina Revilla, Berber, Arturo, Obes. Res. 2000,8 (1), 71-82).

Objects of the invention The main object of the invention is to provide novel N-aryloxypropanolyl-N'- phenethyl ureas useful as appetite suppressant.

Another objective of the invention is to provide a process for the preparation of novel N-aryloxypropanolyl-N'-phenylethyl ureas which are useful as appetite suppressants.

Summary of the invention The present invention relates to the novel N-aryloxypropanolyl-N'-phenylethyl ureas.

These compounds are potentially useful in the treatment of obesity.

Accordingly the present invention relates to a novel N-aryloxypropanolyl-N'- phenethyl urea of general formula 3 wherein R is selected from the group consisting of H, 2, 3 or 4-trifluoromethyl, 2,3, or 4-chloro, 2,3, or 4-bromo, 4-acetyl, 4-propionyl, 4-acetamido, 2,3 or 4 methoxy, 4 nitrile, 2,3 or 4-methyl and 4-formyl and X is S or O.

Formula 3 In one embodiment of the invention, representative compounds of formula 3 are selected from the group consisting of : 3a. N- [2-hydroxy-3- (4-trifluoromethylphenoxy) propyl]-N'-2-phenethyl-urea.

3b. N- [2-hydroxy-3-phenoxypropyl]-N'-2-phenethyl-urea 3c. N- [2-hydroxy-3- (3-trifluoromethylphenoxy) propyl] -N'-2-phenethyl-urea.

3d. N- [3- (4-chlorophenoxy)-2-hydroxypropyl]-N'-2-phenethyl-urea.

3e. N- [3- (4-bromophenoxy)-2-hydroxypropyl]-N'-2-phenethyl-urea.

3f. N- [3- (4-acetylphenoxy)-2-hydroxypropyl]-N'-2-phenethyl-urea.

3g. N- [2-hydroxy-3- (4-propionylphenoxy) propyl]-N'-2-phenethyl-urea.

3h. N- [3- (4-acetamidophenoxy)-2-hydroxypropyl]-N'-2-phenethyl-urea.

3i. N- [2-hydroxy-3- (2-methoxyphenoxy) propyl] -N'-2-phenethyl-urea.

3j. N- [2-hydroxy-3- (4-methoxyphenoxy) propyl] -N'-2-phenethyl-urea.

3k. N- [3- (4-cyanophenoxy)-2-hydroxypropyl]-N'-2-phenethyl-urea.

31. N- [2-hydroxy-3- (2-methylphenoxy) propyl] -N'-2-phenethyl-urea.

3m. N- [2-hydroxy-3- (3-methoxyphenoxy) propyl]-N'-2-phenethyl-urea.

3n. N- [2-hydroxy-3- (4-trifluoromethylphenoxy) propyl] -N'-2-phenethyl-thiourea 3o. N- [2-hydroxy-3- (4-propionylphenoxy) propyl]-N'-2-phenethyl-thiourea.

3p. N- [2-hydroxy-3- (4-methoxyphenoxy) propyl] -N'-2-phenethyl-thiourea.

The invention also provides a process for the preparation of N-aryloxypropanolyl-N'- phenethyl-urea derivatives of the formula 3 wherein X is S or O and R is selected from the group consisting of H, 2,3 or 4-trifluoromethyl, 2,3, or 4-chloro, 2,3, or 4-bromo, 4-acetyl, 4-propionyl, 4-acetamido, 2,3 or 4 methoxy, 4 nitrile, 2,3 or 4-methyl and 4-formyl,

Formula 3 the process comprising reacting a substituted phenolic compound with epichlorohydrin in the presence of alkali carbonate to obtain the corresponding phenoxy epoxy propane which is then reacted with ammonium hydroxide to obtain aminoalcohol of formula 1 OH -- R Formula 1

wherein R is as given above, which is then reacted with a cyanate compound of formula 2 wherein X is oxygen or sulphur NC/X Formula 2

to obtain the compound of formula 3.

In one embodiment of the invention the alkali carbonate is selected from K2CO3 and Na2C03.

In another embodiment of the invention the reaction between compound of formula 1 and compound of formula 2 is carried out in an aprotic solvent selected from the group consisting of CH3CN, CHC13, CH2Cl2. THF and 1, 2-Dichloroethane.

In another embodiment of the invention the reaction between compound of formula 1 and compound of formula 2 is carried out at a temperature in the range of 15-50°C for a period ranging between 5-18 hrs.

In another embodiment of the invention the reaction between compound of formula 1 and compound of formula 2 is carried out in equimolar proportions of compound land compound 2.

The present invention also relates to a pharmaceutical composition comprising compound of formula 3 with one or more conventional additives.

The present invention also relates to a method for the treatment of obesity comprising administering to a subject suffering from obesity, a pharmaceutically effective amount of compound of formula 3.

In one embodiment of the invention, the compound of formula 3 is administered in the form of a pharmaceutical composition of compound of formula 3 with pharmaceutically acceptable additives.

The present invention also provides relates to the use of compound of formula 3 alone or with one or more pharmaceutically acceptable excipients for the treatment of obesity.

In another embodiment of the invention, N- [2-hydroxy-3- [4-trifluoromethylphenoxy] propyl] -N'-2-phenethylurea (3a) shows same activity as Sibutramine.

In another embodiment of the invention (N- [2-hydroxy-3- (4- trifluoromethylphenoxy) propyl] -N'-2-phenethyl-urea, showed a decrease of 41.42% in food intake as compared to food intake in the control group.

In another embodiment of the invention, (N- [2-hydroxy-3- (4- methoxyphenoxy) propyl] -N'-2-phenethyl-urea (compound 3j), showed decrease of 31.82% in food intake as compared to food intake in the control group.

In another embodiment of the invention (N- [2-hydroxy-3- (4- trifluoromethylphenoxy) propyl] -N'-2-phenethyl-thiourea (compound 3n), showed decrease of 28.4% in food intake as compared to food intake in the control group.

In another embodiment of the present invention the compound of formula 3 did not cause any significant change in water intake and gross behaviour.

Brief description of the accompanying drawing Figure 1 illustrates the reaction scheme of the process of the invention.

Detailed description of the invention The present invention provides a novel N-aryloxypropanolyl-N'-phenethyl urea of general formula 3 wherein R is selected from the group consisting of H, 2,3 or 4- trifluoromethyl, 2,3, or 4-chloro, 2,3, or 4-bromo, 4-acetyl, 4-propionyl, 4-acetamido, 2,3 or 4 methoxy, 4 nitrile, 2,3 or 4-methyl and 4-formyl and X is S or 0.

Formula 3 Representative compounds of formula 3 include: 3a. N- [2-hydroxy-3- (4-trifluoromethylphenoxy) propyl]-N'-2-phenethyl-urea.

3b. N- [2-hydroxy-3-phenoxypropyl]-N'-2-phenethyl-urea 3c. N- [2-hydroxy-3- (3-trifluoromethylphenoxy) propyl] -N'-2-phenethyl-urea.

3d. N- [3- (4-chlorophenoxy)-2-hydroxypropyl]-N'-2-phenethyl-urea.

3e. N- [3- (4-bromophenoxy)-2-hydroxypropyl]-N'-2-phenethyl-urea.

3f. N- [3- (4-acetylphenoxy)-2-hydroxypropyl]-N'-2-phenethyl-urea.

3g. N- [2-hydroxy-3- (4-propionylphenoxy) propyl] -N'-2-phenethyl-urea.

3h. N- [3- (4-acetamidophenoxy)-2-hydroxypropyl]-N'-2-phenethyl-urea.

3i. N- [2-hydroxy-3- (2-methoxyphenoxy) propyl] -N'-2-phenethyl-urea.

3j. N- [2-hydroxy-3- (4-methoxyphenoxy) propyl]-N'-2-phenethyl-urea.

3k. N- [3- (4-cyanophenoxy)-2-hydroxypropyl]-N'-2-phenethyl-urea.

31. N-[2-hydroxy-3-(2-methylphenoxy) propyl]-N'-2-phenethyl-urea..

3m. N- [2-hydroxy-3- (3-methoxyphenoxy) propyl]-N'-2-phenethyl-urea.

3n. N- [2-hydroxy-3- (4-trifluoromethylphenoxy) propyl] -N'-2-phenethyl-thiourea 3o. N- [2-hydroxy-3- (4-propionylphenoxy) propyl] -N'-2-phenethyl-thiourea.

3p. N- [2-hydroxy-3- (4-methoxyphenoxy) propyl] -N'-2-phenethyl-thiourea.

The process of preparation of the compound of formula 3 comprises reacting a substituted phenolic compound with epichlorohydrin in the presence of alkali carbonate to obtain the corresponding phenoxy epoxy propane. This is then in turn reacted with ammonium hydroxide to obtain aminoalcohol of formula 1 where R is as given above. The amino alcohol of formula 1 is then reacted with a cyanate compound of formula 2 where X is oxygen or sulphur. This reaction is preferably carried out at a temperature in the range of 15- 50°C for a period ranging between 5-18 hrs. to obtain the compound of formula 3.

The alkali carbonate is selected from K2CO3 and Na2C03 The reaction between compound of formula 1 and compound of formula 2 is carried out in an aprotic solvent such as CH3CN, CHC13, CH2Cl2. THF and 1,2-Dichloroethane.

For example, compounds of the formula (3) can conveniently be made according to the general synthetic route outlined in the Scheme given in the accompanying drawing.

The l-amino-3-aryloxypropan-2-ol of the general formula 1 can be prepared by methods known in the art of preparing analogous compounds eg. by condensing the appropriately substituted phenol with epichlorohydrin in the presence of K2C03/Na2CO3 to give the corresponding aryloxy epoxy propane which in turn were reacted with NH40H to furnish the aminoalcohol of the general formula 1. The process used for this invention comprises of the reaction of one mole equivalent of l-amino-3-aryloxypropan-2-ol of the general formula 1, R=H, 2,3 or 4-trifluoromethyl, 2,3, 4-chloro, 2,3, 4-bromo, 4-acetyl, 4- propionyl, 4-acetamido, 2, 3 or 4 methoxy, 4 nitrile, 2,3 or 4-methyl, and 4 formyl with phenylethyl isocyanate (1. 5 mole)/phenethylisothiocyanate (1 mole) of the general formula 2, in an aprotic, polar solvent in the temperature range of 25° to 30°C for a period range of 5 to 15 hrs to give the corresponding urea (X=O)/thiourea (X=S) derivatives of the formula 3 in the accompanying drawing and isolating the compounds by conventional methods.

It was observed that N- [2-hydroxy-3- [4-trifluoromethylphenoxy] propyl] -N'-2- phenethylurea (3a) shows the same activity as Sibutramine. (N- [2-hydroxy-3- (4- trifluoromethylphenoxy) propyl] -N'-2-phenethyl-urea, showed significant decrease of 41.42% in food intake as compared to food intake in control group. (N- [2-hydroxy-3- (4- methoxyphenoxy) propyl]-N'-2-phenethyl-urea (compound 3j), showed significant decrease of 31.82% in food intake as compared to food intake in control group. (N- [2-hydroxy-3- (4- trifluoromethylphenoxy) propyl]-N'-2-phenethyl-thiourea (compound 3n), showed significant decrease of 28.4% in food intake as compared to food intake in control group. The compound of formula 3 did not cause any significant change in water intake and gross behaviour.

The following examples are given by the way of illustration and should not be construed to limit the scope of present invention.

Example 1: 1- (4-trifluoromethylphenoxy)-2, 3-epoxypropane : A mixture of 4-trifluoromethyl phenol (2g), K2CO3 (2.04g) and epichlorohydrin (lOmL) was stirred at 120°C for 4 hrs. After completion of reaction, the solid was filtered, filtrate was Diluted with water (50mL) and extracted with ethylacetate (3x25mL). Organic layer was washed with Distilled water (3xlOOmL) and concentrated to an oil, which was purified on silica gel column using hexane: ethylacetate (9: 1) as eluant, to give required compound 2.42g (90%) yield. lHNMR (200MHz, CDCl3) : 8 2.75-2. 79 (m, 1gC-3H), 2. 90-2. 95 (m, IH, C-3H), 3.34-3. 38 (m, lH, C-2H), 3.93-4. 01 (dd, lH, J=ll. OHz, J=5.8Hz, C-lH), 4. 26

4.33 (dd, lH, J=ll. lHz, J=2.9Hz, C-lH), 6.96-7. 00 (d, 2H, J=8. 5Hz2&6-ArH), 7. 52-7. 57 (d, 2H, J=8. 6 Hz, 3&5ArH).

MS (m/z): 218 (M+, 100%), 199,188.

Similarly other substituted aryloxyepoxypropane were prepared substituting the 4- trifluoromethyl phenol by an equivalent amount of substituted phenol (J. Med. Chem 1972, 15 , No. 3,286-291.) Example 2: 3-amino-1-(4-trifluoromethylphenoxy)propan-2-ol(1): A solution of 1-(4-trifluoromethylphenoxy)-2, 3-epoxy propane (2g) in MeOH (lOmL) was stirred with NH40H (60mL) at room temperature (18°C) for 24 hrs. The turbid solution was filtered through sintered and filtrate was concentrated. The aqueous layer thus obtained was extracted with CH2C12 (3x 25mL). Combined organic extracts dried (Na2S04) and concentrated to an oil which solidified, 1.68g (74%), m. p 75-77°C. lHNMR (200MHz, CDCl3) 8 1.18 (bs, 2H, NH2), 2.74-2. 95 (m, 2H, CH2NH2), 3. 81- 4.03 (m, 4H, OCH2, CHOH andOH), 6.89-6. 93 (d, 2H, J=8: 7Hz, ArH adjacent to 0), 7.45-7. 49 (d, 2H, J=8.7Hz, ArH adjacent to CF3).

MS (m/z): 236 ((M+1) +, 100%), 221,207.

Similarly other substituted phenoxy propanolamines (la-m) were prepared by substituting the 1- (4-trifluoromethtylphenoxy)-2, 3-epoxypropane with an equivalent amount of 1-(substituted phenoxy)-2, 3-epoxypropanes, (Terent'ev, A. P.; Volodina, M. A. ; Smirnova, M. L.; Mishina, V. G. , Zhur. Obshchei Khim. 29, 3478-82, 1959) Example3 : N- [2-hydroxy-3- (4-trifluoromethylphenoxy) propyl]-N'-2-phenethyl-Urea (3a) To a stirred solution of 3-amino-1-(4-trifluoromethylphenoxy) propan-2-ol (0.235g, lmmol.) in CH3CN (5mL) was added phenylethylisocyanate (0.221g, 1. 5mmol.) slowly within 15min.. Mixture was stirred at 25°C for 12 hrs. till all the amine was consumed.

Stirring discontinued, solvent distilled off, residual oil was washed with hexane (lOmL). The crude material thus obtained was purified by column chromatography using CHCl3 : MeOH (99: 1) as the eluant, yield 74%, m. p. 78-80°C.

1HNMR (200MHz, CDCl3) : # 2.81-2. 84 (t, 2H, J=6. 7Hz,ArCH2), 3.41-3. 48 (m, 4H, NCH2) 3. 9- 4.2 (m, 3H, OCH2, CHOH), 6.93-6. 97 (d, 2H,J=8.4Hz,ArH adjacent to O), 7.16-7. 36 (m, 5H, ArH), 7. 52-7.56 (d, 2H, J=8. 6Hz, ArH adjacent to CF3) MS (m/z): 383 ((M+1) +, 100%), 329,236.

Example 4: N-[2-hydroxy-3-phenoxypropyl]-N'-2-phenethylurea (3b) To a stirred solution of 3-amino-1-phenoxy-propan-2-ol (0. 167g, lmmol.) in CH3CN (5mL) was added phenylethylisocyanate (0. 221g, 1. 5mmol.) slowly within 15 minutes

Mixture was stirred at 25°C for 10 hrs. till all the amine was consumed. Stirring discontinued, solid separated. was filtered off and washed with hexane (lOmL), dried. Yield 85 % w. m p 108°C.

1HONNIR (200MHz, CDC13) : 8 2.81-2. 84 (t, 2H, J=6.8Hz, ArCH2), 3. 41-3. 50 (m, 4H, NCH2), 3.92-4. 1 (m, 3H, OCH2-CHOH), 6. 87-6. 91 (m, 3H, 2,4, 6-OArH), 7. 21-7. 26 (m, 7H, ArH).

MS (m/z): 315 ((M+1)+,100%), 168.

Example 5 : N- [2-hydroxy-3- (3-trifluoromethylphenoxy) propyl]-N'-2-phenethyl- urea (3c) To a stirred solution of 3-amino-1- (3-trifluoromethylphenoxy) propan-2-ol (0.235g, lmmol.) in THF (5mL) was added phenylethylisocyanate (0.221g, 1. 5mmol.) slowly within 15min.. Mixture was stirred at 24°C for 12hrs. till all the amine was consumed. Stirring discontinued, solvent distilled off, residual oil was washed with hexane (lOmL). The crude material thus obtained was purified by column chromatography using CHC13 as the eluant, yield-33%.

1HNMR (200MHz, CDCl3) : 8 2.78-2. 85 (t, 2H, J=6. 8Hz, ArCH2), 3.35-3. 56 (m, 4H, NCH2), 3.94-4. 10 (m, 3H,,OCH2-CH-OH), 7.04-7. 88 (m, 9H, ArH) MS (m/z): 383 ((M+1) +, 100%), 236.

Example 6 : N- [3- (4-chlorophenoxy)-2-hydroxy propyl]-N'-2-phenethyl-urea (3d) To a stirred solution of 3-amino-1- (4-chlorophenoxy) propan-2-ol (0.2015 g, lmmol.) in CH3CN (4mL) was added phenylethylisocyanate (0.221g, 1. 5mmol.) slowly within 15 minutes. Mixture was stirred at 26°C for. lOhrs. till all the amine was consumed.

Stirring discontinued, solid separated was filtered off and washed with hexane (lOmL), dried.

Yield 41 %. m p 100-101°C.

1HNMR (200MHz,CDCl3) : 8 2.77-2. 84 (t, 2H, J=6.8Hz, ArCH2), 3.26-3. 54 (m, 4H, NCH2), 3.87- 4.05 (m, 3H, OCH2-CH-OH), 6.79-6. 84 (d, 2H, J=8. 9Hz, ArH adjacent to O), 7. 16-7. 34 (m, 7H, ArH).

MS (M/Z) : 351 ((M+1) +, 17%), 349 (M+, 55%).

Example 7: N-3- (4 bromophenoxy)-2-hydroxypropylJ-N'-2-phenethyl-urea (3e) To a stirred soln of 3-amino-1- (4-bromophenoxy) propan-2-ol (0.246 g, lmmol.) in CH3CN (5mL) was added phenethylisocyanate (0.221g, 1. 5mmol.) slowly within 15 minutes.

Mixture was stirred at 27°C for 5hrs. till all the amine was consumed Stirring discontinued, solid separated was filtered off and washed with hexane (lOmL), dried. Yield 57 %. m p 115- 116°C.

1HNMR (200MHz, CDC13) : # 2. 77-2. 84 (t, 2H,J=6. 8Hz, ArCH2), 3.26-3. 62 (m, 4H, NCH2), 3. 88- 4.02 (m, 3H, OCH2-CH-OH), 6.75-6. 79 (d, 2H, J=8 7Hz, ArH adjacent to O), 7.16- 7.39 (m, 7H, ArH).

MS (m/z): 393 (M+, 100%), 395((M+2)+, 97%).

Example 8: N- [3- (4-acetylphenoxy)-2-hydroxy propyl]-N'-2-phenethy-lurea (3f) To a stirred solution of 3-amino-I- (4-acetylphenoxy) propan-2-ol (0.209g, lmmol) in 1,2-dichloroethane (5mL) was added phenylethylisocyanate (0.221g, 1. 5mmol.) slowly within 15min.. Mixture was stirred at 26°C for 13 hrs. till all the amine was consumed.

Stirring discontinued, solvent distilled off, residual oil was washed with hexane (lOmL). The crude material thus obtained was purified by column chromatography using CHCl3 : MeOH (99: 1) as the eluant, yield 39%, m. p. 95°C.

1HNMR (200MHz, CDCl3) : 8 2.54- (s, 3H, COCH3), 2.75-2. 82 (t, 2H,J=6.6Hz,ArCH2), 3. 38-- 3.47 (m, 4H, NCH2), 4.10-4. 24 (m, 3H, OCH2-CHOH) ), 6.89-6. 93 (d, 2H, J=8. 6Hz, ArH adjacent to O), 7.19-7. 26 (m, 5H, ArH), 7. 88-7. 93 (d, 2H, J=8. 5Hz, ArH adjacent to carbonyl gr.) MS (m/z): 357 ((M+1)+,35%) Example 9: N-[2-hydroxy-3-(4-propionylphenoxy)propyl]-N'-2-phenethyl-ur ea (3g) To a stirred soln of 3-amino- (4-propionylphenoxy) propan-2-ol (0.223g, lmmol.) in CH3CN (5mL) was added phenylethylisocyanate (0.221g, 1. 5mmol.) slowly within 15 minutes. Mixture was stirred at 26°C for 15 hrs. till all the amine was consumed. Stirring discontinued, solid separated was filtered off and washed with hexane (10mL), dried. Yield 79 %. m p 94-95°C.

'HNMR (200MHzCDCl3). 6 1.17-1. 24- (t, 3H, J=7.3 Hz, CH3), 2. 78- 2. 85 (t, 2H, J=6. 8Hz, ArCH2), 2.89-3. 00 (q, 2H, J=7.3 Hz, COCH2), 3.43-3. 58 (m, 4H, NC H2)), 3. 96-4. 05 (m, 3H, OCH2-CHOH)), 6. 89-6. 94 (d, 2H, J=8. 8Hz, ArH adjacent to O), 7.15- 7.77 (m, 5H, ArH), 7.91-7. 95 (d, 2H,J=8.8Hz,Ar H adjacent to cabonyl gr) MS (m/z): 371 ((M+1)+,48%). <BR> <BR> <BR> <P>Example : N- [3- (4-acetamidophenoxy)-2-hydroxy propyl]-N'-2-phenethyl-urea (3h. ) To a stirred soln of 1-(4-acetamidophenoxy)-3-amino propan-2-ol (0.224g, lmmol.) in CH3CN (5mL) was added phenylethylisocyanate (0.221g, 1. 5mmol. ) slowly within 15 minutes. Mixture was stirred at 25°C for 11 hrs. till all the amine was consumed. Stirring discontinued, solid separated was filtered off and washed with hexane (lOmL), dried. Yield 64%. m p 150-151°C.

1HNMR(200MHz,CDCl3) : # 2.11- (s,3H,COCH3)2.75-2.82(t,2H,J=6.8Hz,ArCH2),3.28- 3.51(m,4H,NCH2), 3.87-4.01(m,3H,OCH2-CH-OH), 6.81-6.85(d,2H,J=8.8Hz,Ar H adjacent to O), 7.18-7. 28 (m, 5H, ArH), 7. 40-7. 45 (d, 2H, J=8. 9Hz, Ar H adjacent to NH gr) MS (m/z) : 372 ((M+1) +, 70%) Example : N-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-N'-2 phenethyl-urea (3i. ) To a stirred solution of 3-amino-1-(2-methoxyphenoxy) propan-2-ol (0. 197g, lmmol.) in CH3CN (4mL) was added phenylethylisocyanate (0.221g, 1. 5mmol.) slowly within 15min.. Mixture was stirred at 26°C for 12 hrs. till all the amine was consumed.

Stirring discontinued, solvent distilled off, residual oil was washed with hexane (lOmL). The crude material thus obtained was purified by column chromatography using CHCl3 : MeOH (98: 2) as the eluant, yield 38%, m. p. 80°C. lHNMR (200MHz, CDCl3) : 8 2.75-2. 82 (t, 2H, J=6. 8Hz, ArCH2) 3.33-3. 57 (m, 4H, NC H2)), 3.79 (s, 3H, OCH3), 3.96-4. 04 (m, 3H, OCH2-CHOH)), 6.90-6. 97 (m, 4H, ArH having OMe gr) 7.16-7. 36 (m, 5H, ArH),) MS (m/z): 345 ((M+1) +, 100%).

Example2 : N- [2-hydroxy-3- (4-methoxyphenoxy) propyl]-N'-2-phenethyl-urea (3j):- To a stirred soln of 3-amino-1-(4-methoxyphenoxy) propan-2-ol (0. 197g, lmmol.) in CH3CN (4mL) was added phenylethylisocyanate (0.221g, 1. 5mmol.) slowly within 15 minutes. Mixture was stirred at 27°C for 8 hrs. till all the amine was consumed. Stirring discontinued, solid separated was filtered off and washed with hexane (lOmL), dried. Yield- 49 %. m. p. 90°C. lHNMR (200MHz, CDCl3) : 8 2. 77-2. 84 (t, 2H, J=6. 7Hz, ArCH2), 3.42-3. 48 (m, 4H, NCH2), 3.76 (s, 3H, OCH3), 3.87-3. 90 (d, 2H, J=6.46Hz, OCH2), 4.00-4. 02 (m, 1H,OHCH),6. 82 (s, 4H, ArH contaning OMe gr), 7. 15-7. 35 (m, 5H, ArH) MS (m/z): 345 ((M+1) +, 100%) Examplel3 : N- [3- (4-cyanophenoxy)-2-hydroxy propyl]-N'-2-phenethyl-urea. (3k):- To a stirred solution of 3-amino-1-(4-cyanophenoxy) propan-2-ol (0. 192g, 1mmol.) in 1,2-dichloroethane (5mL) was added phenylethylisocyanate (0. 221g, 1. 5mmol.) slowly within 15min.. Mixture was stirred at 26°C for 10 hrs. till all the amine was consumed.

Stirring discontinued, solvent distilled off, residual oil was washed with hexane (lOmL). The crude material thus obtained was purified by column chromatography using CHCl3 : MeOH (98: 2) as the eluant, yield 34%, m. p. 80°C.

'HNMR (200MHz, CDCl3) : 8 2.78-2. 85 (t,2H,J=6.7Hz,ArCH2), 3.28-3. 55 (m, 4H, NCH2), 3.95- 4.10 (m, 3H, OCH2-CH-OH), 6.92-6. 99 (d, 2H, J=8. 8Hz, ArH adjacent to O), 7.16-7. 36 (m, 5H, ArH), 7.55-7. 60 (d, 2H, J=8. 8Hz, Ar H adjacent to C-N gr) MS (m/z): 340 ((M+1) +, 93%) Examplel4: N-[2-hydroxy-3-(2-methylphenoxy)propyl]-N'-2-phenethyl-urea (3l.):- To a stirred solution of 3-amino-1-(2-methylphenoxy) propan-2-ol. (0.181g., lmmol.) in CH3CN (5mL) was added phenylethylisocyanate (0. 221g., 1. 5mmol. ) slowly within 15min.. Mixture was stirred at 27°C for 13 hrs. till all the amine was consumed. Stirring discontinued, solvent distilled off, residual oil was washed with hexane (lOmL). The crude material thus obtained was purified by column chromatography using CHC13 as the eluant, yield-37%.

1HNMR (200MHz, CDCl3). 8 2.20 (s, 3H, CH3), 2.76-2. 83 (t, 2H, J=6. 8Hz, ArCH2), 3.34- 3.57 (m, 4H, NCH2), 3.91-4. 08 (m, 3H, OCH2-CH-OH), 6. 79-6.90 (m, 2H, 4&6ArH), 7.10- 7. 32 (m, 7H, ArH).

MS (m/z): 329 ( (M+1) +, 90%).

Example5 : N- [2-hydroxy-3- (3-methoxyphenoxy) propyl]-N'-2-phenethyl-urea (3m. ) :- To a stirred solution of 3-amino-1- (3-methoxyphenoxy) propan-2-ol (0.197g, lmmol.) in CH3CN (5mL) was added phenylethylisocyanate (0.221g, 1. 5mmol.) slowly within 15min.. Mixture was stirred at 28°C for 11 hrs. till all the amine was consumed.

Stirring discontinued, solvent distilled off, residual oil was washed with hexane (lOmL). The crude material thus obtained was purified by column chromatography using CHCl3 : MeOH (99 : 1) as the eluant, yield 86%, m. p. 83-84°C.

1HNMR (200MHz,CDCl3). # 2. 77-2.84 (t, 2H, J=6. 8Hz,ArCH2)3. 35-3.49 (m, 4H, NCH2)), 3.77 (s, 3H, OCH3), 3.89-3. 97 (m, 3H, OCH2-CHOH)), 6.46-6. 54 (m, 3H, ArH ortho to O) 7.13- 7.30 (m, 6H, ArH),) MS (m/z): 345 ((M+1) +, 100%).

Example6 : N- [2-hydroxy-3- (4-trifluoromethylphenoxy) propyl)-N'-2-phenethyl- thiourea (3n) To a stirred solution of 3-amino-1- (4-trifluoromethylphenoxy) propan-2-ol (0. 235g, 1 mmol. ) in CH3CN (6mL) was added phenylethylisothiocyanate (0.163g, 1 mmol.) slowly within 15min.. Mixture was stirred at 25°C for 8 hrs. till all the amine was consumed Stirring discontinued, solid separated was filtered off and crystallized and recrystallised with dichloromethane and hexane, Yield 64 %. , m p = 127°C.

'HNMR (200MHz, CDCl3) : 8 2.89-2. 95 (t, 2H, J=6. 82Hz, ArCH2), 3. 69-3. 8 (m, 4H, NCH2) 3.95- 4.02 (m, 2H, OCH2), 4.2 (m, 1H, CHOH), 6.93-6. 97 (d, 2H,J=8. 7Hz, ArH adjacent to O), 7.19- 7.25 (m, 5H, ArH), 7. 53-7.58 (d, 2H, J=8. 7Hz, ArH adjacent to CF3) MS (m/z): 399 ((M+1) +, 93%) Example 17: N-[2-hydroxy-3-(4-propionylphenoxy)propyl]-N'-2-phenethyl-th iourea (3o) To a stirred solution of 3-amino-1- (4-propionylphenoxy) propan-2-ol (0.223g, 1 mmol) in CH3CN (6mL) was added phenylethylisothiocyanate (0.163g, 1 mmol. ) slowly within 15min.. Mixture was stirred at 26°C for 9 hrs. till all the amine was consumed. Stirring discontinued, solid separated was filtered off and crystallized and recrystallised with dichloromethane and hexane, Yield 64 %., m p = 125°C.

1HNMR (200MHzCDCl3) : 51. 17-1.24 (t,3H,J=7. 2 Hz, CH3), 2.88-2. 99 (m, 4H, COCH2, ArCH2), 3.63-3. 79 (m, 4H, NCH2)), 3.96-4. 08 (m, 2H, OCH2), 4.15-4. 19 (m, lH, CHOH), 6. 88- 6.93 (d, 2H, J=8.8Hz, ArH adjacent to O), 7.19-7. 33 (m, 5H, ArH), 7.90-7. 95 (d, 2H, J=8. 8Hz, Ar H adjacent to cabonyl gr) MS (m/z): 387 ((M+1) +, 100%).

Example 18 : N- [2-hydroxy-3- (4-methoxyphenoxy) propyl]-N'-2-phenethyl-thiourea (3p) To a stirred solution of 3-amino-1-(4-methoxyphenoxy) propan-2-ol (0.197g., 1 mmol. ) in CH3CN (5mL) was added phenylethylisothiocyanate (0.163g, 1 mmol. ) slowly within 15min.. Mixture was stirred at 26°C for 9 hrs. till all the amine was consumed Stirring discontinued, solid separated was filtered off and crystallized and recrystallised with dichloromethane and hexane, Yield-72 %, m p = 74-76°C.

1HNMR (200MHz, CDCl3) : 8 2.87-2. 94 (m, 2H, ArCH2), 3.58-3. 93 (m, 9H, NCH2, OCH3, OCH2)),4.11 (m,1H, CHOH)), 6.81-6.82(s,4H,ArH containing OMe gr.), 7.22-7.26(m,5H, ArH),) MS(m/z): 361((M+1)+,100%).

Advantage The pharmacological evaluation of the test compounds of general formula 3 was carried out by the following protocol.

The appetite suppressant activity of test compounds was tested on scheduled fed rat model of appetite. The study was conducted in adult male Sprague Dawley rats, weighing 175-200 g on arrival). The animals were housed in transparent cages of Bayer Makrolon type 3118 measuring 425 x 266 x 180 with floor area 800 cm2. In each cage one rat was kept. A special fat rich diet (Diet # 12451, Research Diets, NJ, USA) was provided only for 3 h (1 lam-2 pm) daily [no diet in rest of the period]. Water was provided for 24 h. Diet was

weighed prior to and after observation period by an electronic [Digital display] balance. Food intake was recorded by calculating the difference between prior and after weight of diet. Rats were weighed weekly after feeding. Rats were provided 16 g of diet daily and within 12-14 days animals achieved base line food intake (12-14 g) with gain in body weight (230-250 g) indicating adaptation to scheduled feeding. Only those rats that adapted to schedule feeding were used in the study. Rat showing significant less food intake and weight gain as compared to others was excluded from the study.

Thereafter, tests compounds dissolved in 10% DMSO aqueous solution and given in dose of 20 Fmol/kg, by oral route. The test compounds were administered 30 min prior to food. Each test compounds were given in 5 rats. Diet and water was weighed at hourly interval in control and compound treated rats. During the period of feeding the gross behavior of rat was also observed.

The significance of difference between the food intake of treated and control groups was determined by unpaired Student's t test [Two tailed p value].

The compound 3a, chemically, (N- [2-hydroxy-3- (4- trifluoromethylphenoxy) propyl] -N'-2-phenethyl-urea. , showed significant decrease of 41.42% in food intake as compared to food intake in the control group. The compound 3a did not cause any significant change in water intake and gross behaviour. Moreover, the decrease showed by the compound 3a was comparable with the decrease in food intake (38.57 %) caused by Sibutramine (20 llmol/kg, by oral route).

The compound 3j, chemically, (N- [2-hydroxy-3- (4- methoxyphenoxy) propyl] -N'-2- phenethyl-urea. , showed significant decrease of 31.82% in food intake as compared to food intake in the control group. The compound 3j did not cause any significant change in water intake and gross behaviour..

The compound 3n, chemically, (N- [2-hydroxy-3- (4- trifluoromethylphenoxy) propyl] -N'-2-phenethyl-thiourea. , showed significant decrease of 28.4% in food intake as compared to food intake in the control group. The compound 3n did not cause any significant change in water intake and gross behaviour.

The advantage of the present invention is that it provide a new class of compounds which are appetite suppressants and are simple than the existing standard drug sibutramine.

The starting materials of the compounds of the present invention are cheap and are easily available. The process described here in simple economically feasible and ecofriendly.